{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma&page=20", "query": { "condition": "Pancreatic Carcinoma", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 2231, "total_pages": 224, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T21:38:53.884Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03006302", "title": "Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "CRS-207", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "GVAX Pancreas Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-01-31", "completion_date": "2024-08-05", "has_results": true, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-10-15T21:38:53.884Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03006302" }, { "nct_id": "NCT00394602", "title": "Chemoradiation-Induced Nausea and Emesis: Quality of Life", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gastric Cancer", "Pancreatic Cancer", "Cervical Cancer", "Vulvar Cancer", "Endometrial Cancer", "Anal Cancer" ], "interventions": [ { "name": "Interview", "type": "BEHAVIORAL" }, { "name": "Questionnaire", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 207, "start_date": "2004-04-07", "completion_date": "2019-05-08", "has_results": false, "last_update_posted_date": "2020-01-02", "last_synced_at": "2026-10-15T21:38:53.884Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00394602" }, { "nct_id": "NCT01064622", "title": "Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage IV Pancreatic Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Hydrocortisone/Placebo", "type": "OTHER" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 118, "start_date": "2009-09-03", "completion_date": "2013-01-31", "has_results": true, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-10-15T21:38:53.884Z", "location_count": 25, "location_summary": "Beverly Hills, California • Duarte, California • Los Angeles, California + 19 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01064622" }, { "nct_id": "NCT06188702", "title": "S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "MTAP-deleted Solid Tumors" ], "interventions": [ { "name": "S095035", "type": "DRUG" }, { "name": "TNG462", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Servier Bio-Innovation LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2024-04-29", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T21:38:53.884Z", "location_count": 5, "location_summary": "Lake Mary, Florida • Indianapolis, Indiana • Maumee, Ohio + 2 more", "locations": [ { "city": "Lake Mary", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Maumee", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06188702" }, { "nct_id": "NCT00003760", "title": "Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "irofulven", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "1998-11", "completion_date": "2000-05", "has_results": false, "last_update_posted_date": "2012-08-09", "last_synced_at": "2026-10-15T21:38:53.884Z", "location_count": 3, "location_summary": "Omaha, Nebraska • Fort Sam Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Fort Sam Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003760" }, { "nct_id": "NCT00428220", "title": "A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Breast Cancer", "Advanced Breast Cancer", "Metastatic Castration Resistant Prostate Cancer", "Metastatic Renal Cell Cancer", "Non-Small Cell Lung Cancer", "Thyroid Cancer", "Advanced/Metastatic Non-Small Cell Lung Cancer", "Advanced Gastric Cancer", "Gastrointestinal Stromal Tumor", "Hepatocellular Carcinoma", "Pancreatic Islet Cell Carcinoma", "Pancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 223, "start_date": "2007-07", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2019-06-27", "last_synced_at": "2026-10-15T21:38:53.884Z", "location_count": 15, "location_summary": "Atlanta, Georgia • Maywood, Illinois • Iowa City, Iowa + 7 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00428220" }, { "nct_id": "NCT02782182", "title": "Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2016-06-28", "completion_date": "2018-03-29", "has_results": false, "last_update_posted_date": "2019-03-19", "last_synced_at": "2026-10-15T21:38:53.884Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02782182" }, { "nct_id": "NCT02910882", "title": "PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma Non-resectable" ], "interventions": [ { "name": "PEGylated Recombinant Human Hyaluronidase (PEGPH20)", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Scripps Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "90 Years", "sex": "ALL", "summary": "Up to 90 Years" }, "enrollment_count": 4, "start_date": "2017-01-03", "completion_date": "2018-08-31", "has_results": false, "last_update_posted_date": "2019-04-11", "last_synced_at": "2026-10-15T21:38:53.884Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02910882" }, { "nct_id": "NCT00112528", "title": "Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2005-06", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2016-12-13", "last_synced_at": "2026-10-15T21:38:53.884Z", "location_count": 201, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 127 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112528" }, { "nct_id": "NCT04083599", "title": "GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Solid Tumor", "Non-Small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Melanoma", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "GEN1042", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2019-09-17", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-15T21:38:53.884Z", "location_count": 23, "location_summary": "Anchorage, Alaska • Los Alamitos, California • San Diego, California + 19 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Los Alamitos", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT04083599" } ] }